Last reviewed · How we verify

OCTA-C1-INH — Competitive Intelligence Brief

OCTA-C1-INH (OCTA-C1-INH) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant C1-esterase inhibitor. Area: Immunology / Rare Disease.

phase 3 Recombinant C1-esterase inhibitor C1-esterase inhibitor (C1-INH) Immunology / Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

OCTA-C1-INH (OCTA-C1-INH) — Octapharma. OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OCTA-C1-INH TARGET OCTA-C1-INH Octapharma phase 3 Recombinant C1-esterase inhibitor C1-esterase inhibitor (C1-INH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant C1-esterase inhibitor class)

  1. Octapharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OCTA-C1-INH — Competitive Intelligence Brief. https://druglandscape.com/ci/octa-c1-inh. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: